Miltenyi Biotec

What Miltenyi Biotec does

Miltenyi Biotec is a privately held German biotechnology company founded in 1989 and headquartered in Bergisch Gladbach, with 1,001-5,000 employees and operations across Europe and South Asia. The company designs, develops, manufactures, and integrates products that support biomedical research and enable cell and gene therapy, and is identified as a top-5 player in the global cell and gene therapy tools and reagents market alongside Thermo Fisher Scientific, Cytiva (Danaher), Merck KGaA, and Sartorius.

Its core product portfolio centers on the CliniMACS Prodigy, an automated, closed-system manufacturing platform for therapeutic cells, combined with proprietary magnetic-activated cell sorting (MACS) reagents and consumables for cell enrichment (e.g., CD34+ stem cells, NK cells from umbilical cord blood). The company acquired Lino Biotech in February 2023 to add a biosensor platform for molecular interaction measurement, extending its offering into quality control and bioprocess monitoring. It is also developing ZAMTO Cell, a dual-target CAR-T cancer therapy targeted for 2026 availability in India, signaling a move from purely enabling tools into therapeutic product development. Additional acquisitions across its history (LaVision BioTec, Sensovation AG, Lentigen, Owl biomedical, Eligix) have built a vertically integrated instruments, reagents, and vectors portfolio.

Miltenyi Biotec generates revenue primarily through the sale of cell and gene therapy tools, reagents, and consumables, alongside the sale and service of automated manufacturing systems such as the CliniMACS Prodigy. Pricing is not publicly disclosed; the company sells through a direct enterprise field sales motion to pharmaceutical companies, biotech firms, academic and clinical research organizations, and hospitals, supplemented by event-driven marketing and reference sites such as the Hyderabad Cell and Gene Therapy Center of Excellence opened in February 2025. Leadership includes Founder, Managing Director, President, and CEO Stefan Miltenyi, CFO and Managing Director Norbert Henschel, and President of North America Markus Weiss.

Name

Miltenyi Biotec

Legal name

Miltenyi Biotec

Website

https://miltenyibiotec.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Miltenyi Biotec is a privately held German biotechnology company that designs, manufactures, and integrates cell and gene therapy tools, reagents, and automated manufacturing systems, serving pharmaceutical, biotech, academic, and hospital customers globally.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy Manufacturing Technologies

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI)

Keywords

• Cell therapy manufacturing
• Gene therapy solutions
• Magnetic cell separation
• Biomedical research reagents
• CAR-T cell therapy

Headquarters

HQ city

Bergisch Gladbach

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Cell and Gene Therapy Tools and Reagents: Sale of reagents, consumables, and tools for cell and gene therapy development and manufacturing including magnetic cell separation reagents, culture media, and biosensors.
2. Automated Cell Therapy Processing Systems: Sale and service of automated manufacturing systems (CliniMACS Prodigy) for closed-system cell therapy processing used in clinical and commercial manufacturing.
3. Cell Therapy Technologies: Comprehensive cell therapy technology solutions including instruments, reagents, and consumables for personalized and regenerative medicine applications.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Miltenyi Biotec designs, develops, manufactures, and integrates products that empower biomedical research and enable cell and gene therapy. The company sells automated closed-system cell therapy processing platforms (e.g., CliniMACS Prodigy), magnetic cell separation reagents and instruments, molecular interaction biosensors (via Lino Biotech), and a comprehensive portfolio of tools and reagents used in research, clinical, and commercial cell therapy manufacturing.

Product overview

Miltenyi Biotec offers a unified portfolio centered on cell and gene therapy solutions. The core offerings include the CliniMACS Prodigy automated manufacturing system, the ZAMTO Cell dual-target CAR-T therapy (in development), and the Lino Biotech biosensor platform (acquired in 2023). These products are complemented by a comprehensive range of tools and reagents for cell and gene therapy development, manufacturing, and quality control. The company operates India\'s first Cell and Gene Therapy Center of Excellence in Hyderabad.

Differentiator

Problem solved

Functional benefit

Products and services

• CliniMACS Prodigy Automated, closed-system manufacturing platform for therapeutic cells including NK cells and CD34+ stem cell enrichment, used by clinical and commercial cell therapy manufacturers for scalable, GMP-compliant production.
• ZAMTO Cell Dual-target CAR-T cancer therapy product developed by Miltenyi Biotec India, intended for oncology treatment.
• Lino Biotech Biosensor Platform Biosensor technology for molecular interaction measurement, integrated with Miltenyi's cell and gene therapy approaches to enhance quality control and reduce costs in bioprocessing and drug discovery.
• Cell and Gene Therapy Tools and Reagents Comprehensive portfolio of magnetic cell separation reagents, culture media, instruments, consumables, and related tools supporting cell and gene therapy development, manufacturing, and quality control.

Quantifiable outcome

• Automated NK cell manufacturing demonstrates consistent efficiency in CD34+ stem cell enrichment regardless of initial cell content or sample age
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered minor, major, strategic and core.

• BioAsia 2026minorGTM or Marketing Partner · 17 February 2026Active participation at BioAsia 2026 conference in Hyderabad with executives featured as keynote speakers and panel participants discussing TechBio innovation and the future of life sciences.
• BIRACmajorStrategic or Co-development Partner · 18 June 2025Miltenyi Biotec India and BIRAC (Biotechnology Industry Research Assistance Council) signed a Letter of Intent to advance India's cell and gene therapy ecosystem, supporting the development of domestic manufacturing capabilities and technology transfer.
• PioneerstrategicStrategic or Co-development Partner · 2 April 2025Strategic partnership unveiled at Victoria House, positioning collaboration in cell and gene therapy development and manufacturing capabilities.
• THSTI (Translational Health Science and Technological Institute)majorStrategic or Co-development Partner · 18 July 2024Collaboration to strengthen R&D in cell and gene therapy for cancer treatment, combining Miltenyi Biotec's technology platforms with THSTI's research capabilities to advance cell therapy development in India.
• Lino BiotechcoreStrategic or Co-development Partner · 22 February 2023Miltenyi Biotec acquired 100% of Lino Biotech, a Swiss biosensor company specializing in molecular interaction measurement. The acquisition aims to integrate the biosensor platform with Miltenyi's cell and gene therapy approaches to enhance quality control and reduce costs in bioprocessing and drug discovery.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Merck KGaA (MilliporeSigma): Named peer in CGT tools and reagents, with deep overlap in bioprocessing consumables, cell culture media, and gene therapy manufacturing solutions through its Life Science division.
• Cytiva (Danaher): Named peer in CGT tools and reagents. Provides cell therapy manufacturing platforms, single-use bioprocessing, and instruments as part of Danaher's broader life-sciences portfolio.
• Thermo Fisher Scientific: Identified by Miltenyi as one of its top-5 peers in the global CGT tools and reagents market. Operates across instruments, reagents, and CDMO services with significantly greater scale.
• Lonza: Major CDMO and cell/gene therapy manufacturing solutions provider. Competes with Miltenyi in automated, closed-system cell processing and CGT process development.
• Charles River Laboratories: Provides research models, cell and gene therapy CRO/CDMO services, and bioprocessing solutions with overlapping CGT manufacturing capabilities.
• Beckman Coulter Life Sciences (Danaher): Part of Danaher's life-sciences portfolio; provides flow cytometry and cell-sorting instruments that compete with Miltenyi's MACS separation technology in research and clinical workflows.

Direct peers

• Sartorius: Co-vendor with Miltenyi in the German automated/closed cell therapy processing market. Directly competes in cell therapy bioprocessing equipment, bioreactors, and consumables.
• MaxCyte: Provides electroporation-based cell engineering and processing platforms used in CGT manufacturing. Competes with Miltenyi's CliniMACS Prodigy for cell therapy workflow integration.
• STEMCELL Technologies: Specialty reagents, media, and instruments for cell isolation, culture, and differentiation. Directly competes with Miltenyi's cell separation reagents and stem cell workflows.
• Bio-Techne: Provides reagents, proteins, and cell/gene therapy workflow tools. Competes with Miltenyi in research and process-development reagents for immunology and regenerative medicine.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/miltenyibiotec
• Facebookfacebook.com/miltenyibiotecofficial
• LinkedInlinkedin.com/company/miltenyi-biotec

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Miltenyi Biotec